Related Experiment Videos
The LGM Vena-Tech caval filter: results of a multicenter study
J B Ricco1, F Dubreuil, P Reynaud
1Centre de Pilotage, Centre Hospitalier Universitaire, Poitiers, France.
Annals of Vascular Surgery
|January 1, 1995
Summary
The LGM Vena-Tech caval filter effectively prevents pulmonary embolism with few complications. Its long-term safety is unknown, so use it only when heparin fails or is contraindicated.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Cardiology
Background:
- Pulmonary embolism (PE) prevention is crucial.
- Caval filters are essential for PE prevention.
- The LGM Vena-Tech filter has been used in Europe since 1989.
Purpose of the Study:
- Evaluate the efficacy of the LGM Vena-Tech percutaneous caval filter.
- Assess complications associated with the LGM Vena-Tech filter.
- Determine the filter's long-term outcomes.
Main Methods:
- Prospective multicenter study.
- 222 patients received LGM Vena-Tech filter placement (Sept 1989 - Dec 1991).
- Filters were percutaneously placed via jugular, subclavian, or femoral veins.
Main Results:
- In-hospital mortality: 1.7%.
- Recurrent PE rate: 93.2% freedom at 30 months.
- Inferior vena cava thrombosis: 94% patency at 30 months.
- Filter migration occurred in 3.6% without complications.
- Filter tilting did not correlate with recurrent PE.
Conclusions:
- The LGM Vena-Tech caval filter provides satisfactory PE prevention with a low complication rate.
- Long-term filter fate requires further investigation.
- Restrict use to patients where heparin is contraindicated or ineffective.